Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study

Key Points

• S-1 administration post-capecitabine toxicity shows a promising safety profile for colon cancer patients undergoing adjuvant treatment.
• Among patients experiencing toxicity, manageable adverse effects were observed, supporting the use of S-1 as an alternative.
• Population-based study assesses real-world outcomes, enhancing understanding of treatment options for colon cancer survivors after toxicity.
• Findings suggest the need for further research into S-1's role, given the potential for effective adjuvant treatment following capecitabine.